Belgium seeking to put ex-official on trial over killing of Congo's Lumumba
Belgian prosecutors said Tuesday that they were seeking to put a 92-year-old former diplomat on trial over the 1961 killing of Congolese leader Patrice Lumumba.
Etienne Davignon is the only one still alive among 10 Belgians who were accused of complicity in the murder of the independence icon in a 2011 lawsuit filed by Lumumba's children.
If he goes on trial, Davignon would be the first Belgian official to face justice in the more than six decades since Lumumba was murdered.
A fiery critic of Belgium's colonial rule, Lumumba became his country's first prime minister after it gained independence in 1960.
02:09
But he fell out with the former colonial power and with the United States and was ousted in a coup a few months after taking office.
He was executed on January 17, 1961, aged just 35, in the southern region of Katanga, with the support of Belgian mercenaries.
His body was dissolved in acid and never recovered.
Davignon, who went on to be a vice president of the European Commission in the 1980s, was a trainee diplomat at the time of the assassination.
He is accused of involvement in the "unlawful detention and transfer" of Lumumba at the time he was taken prisoner and his "humiliating and degrading treatment", the prosecutor's office said.
But prosecutors added that a charge of intent to kill should be dropped.
It is now up to a magistrate to decide if the trial should proceed, following a hearing on the case set for January 2026.
"We're moving in the right direction. What we're seeking is, first and foremost, the truth," Juliana Lumumba, the daughter of the former Congolese premier, told Belgian broadcaster RTBF.
The prosecutor's decision is the latest step in Belgium's decades-long reckoning with the role it played in Lumumba's killing.
In 2022, Belgium returned a tooth -- the last remains of Lumumba -- to his family in a bid to turn a page on the grim chapter of its colonial past.
The tooth was seized by Belgian authorities in 2016 from the daughter of a policeman, Gerard Soete.
A Belgian parliamentary commission of enquiry concluded in 2001 that Belgium had "moral responsibility" for the assassination, and the government presented the country's "apologies" a year later.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Le Figaro
9 hours ago
- Le Figaro
Palestinism, Electoral Calculations, Tribalization… The Lessons of an Explosive Report on Belgium, Now a 'Laboratory' of Antisemitism
Réservé aux abonnés The Jonathas Institute, a center for the study of antisemitism, delivers for the first time a staggering assessment of Belgian society. Has Belgium been under a kind of omerta until now? That's the question raised by the Jonathas Institute, a Belgian research center, in its explosive report on antisemitism, supported by the Wallonia-Brussels Federation, one of Belgium's three federated communities. Reviewed by Le Figaro, this 76-page analysis, based in part on an Ipsos poll, paints a disturbing picture of a deeply divided society — one that is, in some respects, more antisemitic than France. 'In a context marked by a resurgence of antisemitic acts and rhetoric, surveying Belgians about their perceptions of Jews seemed obvious. And yet, no public, media, academic, or civil society actor has undertaken such a large-scale study in recent memory,' the report notes. The institute is led by Joël Kotek, an emeritus university professor and former lecturer at Sciences Po Paris, and Joël Amar, an advisor to the presidents of the Representative Council of French Jewish Institutions (CRIF). The authors observe that 'in contrast, studies…
Euronews
11 hours ago
- Euronews
EU shuts out Chinese medical suppliers from European market
The European Commission has formally introduced restrictions previously reported by Euronews in response to what it describes as discriminatory barriers imposed by China against European medical device manufacturers. Following a detailed investigation, the Commission found "clear evidence" that China had been unfairly blocking EU-made medical devices from its public procurement market. This marks the first countermeasure taken under the International Procurement Instrument (IPI), which came into force in August 2022 to promote fair access for EU firms to procurement opportunities outside the bloc. 'Our aim with these measures is to level the playing field for EU businesses. We remain committed to dialogue with China to resolve these issues,' said Trade Commissioner Maroš Šefčovič. Under the new rules, Chinese companies are barred from bidding on public contracts for medical devices in the EU single market that exceed €5 million. Additionally, successful bids must contain no more than 50% of inputs originating from China. According to the Commission, the measures are proportionate to China's own restrictions and are designed to ensure the continued availability of critical medical equipment for EU healthcare systems. Exceptions will apply in cases where no viable alternative suppliers are available. The Commission pointed out that the decision aligns with international trade obligations, including those under the World Trade Organization (WTO), noting that the EU has no binding procurement commitments with China. EU-based medical device companies have long struggled to access China's procurement market, despite China being one of the bloc's largest export destinations for such products, accounting for 11% of exports in 2022. The Commission's investigation focused on China's government procurement law, which enforces a "Buy China" policy, requiring public institutions to prioritise domestic products and services. The probe identified several barriers faced by EU firms, including opaque approval processes, discriminatory certification practices, ambiguous national interest clauses used to exclude foreign suppliers, and unsustainable pricing requirements. According to a 2025 Commission report, 87% of public procurement contracts for medical devices in China were subject to exclusionary and discriminatory practices against EU suppliers. The new EU measures come at a delicate moment in EU-China relations, which are undergoing a cautious diplomatic reset. Both sides have intensified efforts to manage longstanding disputes amid shifting global dynamics, including the aftermath of the Trump-era trade wars and ongoing US-China tensions. A key milestone in this renewed dialogue is the upcoming EU-China Summit, now scheduled to take place in Beijing in the second half of July 2025. Meanwhile, reciprocal actions continue to define the trade relationship. China has extended its anti-dumping investigation into EU pork imports by six months, while the EU recently imposed tariffs of up to 45% on Chinese electric vehicles (EVs), reflecting a strategic pattern of targeting politically sensitive industries ahead of high-level negotiations.
France 24
13 hours ago
- France 24
EU bars Chinese firms from major state medical equipment contracts
The latest salvo in trade tensions between the 27-nation bloc and China covers a wide range of healthcare supplies, from surgical masks to X-ray machines, that represent a market worth 150 billion euros in the EU. "Our aim with these measures is to level the playing field for EU businesses," the bloc's trade commissioner Maros Sefcovic said. "We remain committed to dialogue with China to resolve these issues." In response, China accused the EU of "double standards". "The EU has always boasted that it is the most open market in the world, but in reality, it has gradually moved towards protectionism", foreign ministry spokesman Guo Jiakun said at a regular press briefing. "Under the guise of fair competition (the EU) actually carries out unfair competition, which is a typical case of double standards." The European Commission said in a statement the move was in "response to China's longstanding exclusion of EU-made medical devices from Chinese government contracts." Brussels said just under 90 percent of public procurement contracts for medical devices in China "were subject to exclusionary and discriminatory measures" against EU firms. In addition to barring Chinese firms from major state purchases, "inputs from China for successful bids" would also be limited to 50 percent, it said. Over the last three years, Brussels and Beijing have come into conflict in a number of economic sectors, including electric cars, the rail industry, solar panels and wind turbines. The decision on medical devices comes at a time of heightened trade tensions with President Donald Trump's United States, which has imposed customs surcharges on imports from all over the world, including Europe. The EU has decided to take a tougher stance on trade in recent years, adopting a vast arsenal of legislation to better defend its businesses against unfair competition. In April 2024, the commission opened an investigation into Chinese public contracts for medical devices, the first under a new mechanism introduced by the EU in 2022 to obtain better access to overseas state purchases. China, on the other hand, accuses Europe of protectionism. After a year of negotiations, the commission, which manages trade policy on behalf of the 27 member states, said it had failed to make any progress with China. "The measure seeks to incentivise China to cease its discrimination against EU firms and EU-made medical devices and treat EU companies with the same openness as the EU does with Chinese companies and products," Brussels said.
